Thomas Sandgaard, CEO of Zynex explains: "It was very important to us to obtain this accreditation before the September 30 deadline. Not only do we maintain our status of being a provider to Medicare, but our customers know that we have met the high standards and procedures which are required for accreditation. Other providers that are not able to comply with these standards will be excluded from being a provider to Medicare and several private health insurance companies in the future."
About Zynex
Zynex, Inc. (founded in 1996) engineers, manufactures, markets and sells its own design of electrotherapy medical devices in two distinct markets: standard digital electrotherapy products for pain relief and pain management; and the NeuroMove(TM) for stroke and spinal cord injury (SCI) rehabilitation. Zynex's product lines are fully developed, FDA-cleared, commercially sold, an have been developed to uphold the Company's mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain.
Safe Harbor Statement
Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital in order to grow our business, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement from insurance companies for products sold or rented to our customers, acceptance of our products by health insurance providers, acceptance of our products by hospitals and clinicians, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the uncertain outcome of pending material litigation and other risks described in our 10-K Report for the year ended December 31, 2008.
SOURCE: Zynex, Inc.
Zynex, Inc. Thomas Sandgaard, 303-703-4906 CEO www.zynexmed.com

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index